secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fulcrum Therapeutics, Inc. (FULC)
CIK:        0001680581
Form:       8-K
Filed at:   2025-10-29T23:59:59+00:00
Accession:  0001193125-25-254619
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fulcrum Therapeutics Q3 loss $19.6M; pociredir 20mg cohort enrolled, data due year-end
--------------------------------------------------------------------------------

- Cash, equivalents and marketable securities $200.6M; cash runway into 2028.
- Net loss $19.6M in Q3 2025 versus $21.7M in Q3 2024; R&D spend $14.3M.
- 12 mg dose cohort of Phase 1b PIONEER trial showed dose-dependent HbF increase and VOC reduction.
- Enrollment completed in 20 mg dose cohort (n=12); data expected by year-end 2025.
- Plans to submit IND for bone marrow failure syndromes (DBA, 5q-, etc.) in Q4 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680581/000119312525254619/0001193125-25-254619-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680581/000119312525254619/fulc-20251029.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-254619

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer